Edgewise Therapeutics Inc’s filing revealed that its Chief Scientific Officer Russell Alan J unloaded Company’s shares for reported $6004.0 on Mar 07 ’25. In the deal valued at $30.02 per share,200 shares were sold. As a result of this transaction, Russell Alan J now holds 14,863 shares worth roughly $0.39 million.
Then, KOCH KEVIN sold 100 shares, generating $3,000 in total proceeds. Upon selling the shares at $30.00, the President and CEO now owns 14,478 shares.
Before that, Russell Alan J sold 8,015 shares. Edgewise Therapeutics Inc shares valued at $240,623 were divested by the Chief Scientific Officer at a price of $30.02 per share. As a result of the transaction, Russell Alan J now holds 14,863 shares, worth roughly $0.39 million.
Scotiabank initiated its Edgewise Therapeutics Inc [EWTX] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $50. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in late January with a ‘”a Hold”‘ rating. Evercore ISI began covering EWTX with “an Outperform” recommendation on November 22, 2024. Piper Sandler started covering the stock on March 07, 2024. It rated EWTX as “an Overweight”.
Price Performance Review of EWTX
On Monday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock jump 2.96% to $26.43. Over the last five days, the stock has lost -4.00%. Edgewise Therapeutics Inc shares have fallen nearly -1.01% since the year began. Nevertheless, the stocks have risen 51.81% over the past one year. While a 52-week high of $38.12 was reached on 02/06/25, a 52-week low of $14.90 was recorded on 01/13/25. SMA at 50 days reached $26.77, while 200 days put it at $25.16.
Levels Of Support And Resistance For EWTX Stock
The 24-hour chart illustrates a support level at 25.26, which if violated will result in even more drops to 24.08. On the upside, there is a resistance level at 27.13. A further resistance level may holdings at 27.82. The Relative Strength Index (RSI) on the 14-day chart is 49.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.23%. Stochastics %K at 34.27% indicates the stock is a holding.
How much short interest is there in Edgewise Therapeutics Inc?
A steep rise in short interest was recorded in Edgewise Therapeutics Inc stocks on 2025-02-28, growing by 1.68 million shares to a total of 8.73 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 7.06 million shares. There was a rise of 19.21%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating .
